Myfortic (Mycophenolic Acid)

Mycophenolic Acid, the active ingredient in Myfortic, is an immunosuppressant presented as an oral delayed‑release tablet for systemic use. It is indicated for the prevention of organ rejection in kidney, heart and liver transplantation, helping to maintain graft function in adult recipients.

GNH USA supplies Myfortic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide. The product complies with EU regulatory standards and is manufactured under strict quality controls.

Myfortic is an antimetabolite immunosuppressant used in transplantation to inhibit lymphocyte proliferation.

- Kidney transplantation: prevents acute and chronic rejection, supporting graft survival. - Heart transplantation: reduces incidence of rejection episodes, aiding long‑term cardiac graft function. - Liver transplantation: helps maintain liver graft tolerance and decreases rejection risk.

Myfortic may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Gastrointestinal discomfort: nausea, vomiting, diarrhea, or abdominal pain. - Infections: increased susceptibility to bacterial, viral or fungal infections. - Hematologic changes: anemia, leukopenia, or thrombocytopenia. - Headache: mild to moderate intensity.

Serious or Rare Side Effects: - Severe infection: opportunistic or life‑threatening infections. - Progressive renal dysfunction: worsening kidney function. - Malignancy: increased risk of certain cancers. - Bone marrow failure: aplastic anemia or pancytopenia.

When prescribing Myfortic, clinicians should consider several safety precautions to minimize risks. - Monitor blood counts: perform regular complete blood count testing to detect cytopenias. - Assess renal function: adjust therapy based on creatinine clearance and monitor for nephrotoxicity. - Screen for infections: evaluate for active infections before initiation and during treatment. - Avoid pregnancy: discuss contraception as the drug may harm the fetus. - Drug interactions: review concomitant medications that affect IMPDH or increase infection risk. - Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture and light.

Myfortic can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Antimetabolites (e.g., azathioprine): additive immunosuppression may increase infection risk. - Live vaccines: heightened risk of vaccine‑derived infection. - Strong CYP3A4 inducers (e.g., rifampin): may reduce mycophenolic acid exposure.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may decrease absorption of mycophenolic acid. - ACE inhibitors or ARBs: combined use may affect renal function. - Cholesterol‑lowering agents (e.g., statins): monitor for increased mycophenolic acid levels.